24,242 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Purchased by Oak Ridge Investments LLC

Oak Ridge Investments LLC acquired a new stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 24,242 shares of the company's stock, valued at approximately $1,942,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in PROCEPT BioRobotics by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 4,184,585 shares of the company's stock worth $175,376,000 after acquiring an additional 109,694 shares in the last quarter. Diversified Trust Co boosted its stake in PROCEPT BioRobotics by 25.4% in the 1st quarter. Diversified Trust Co now owns 13,442 shares of the company's stock worth $664,000 after purchasing an additional 2,725 shares in the last quarter. Principal Financial Group Inc. lifted its stake in PROCEPT BioRobotics by 98.2% during the 1st quarter. Principal Financial Group Inc. now owns 20,983 shares of the company's stock valued at $1,037,000 after acquiring an additional 10,395 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of PROCEPT BioRobotics by 0.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 60,116 shares of the company's stock valued at $2,971,000 after acquiring an additional 336 shares during the last quarter. Finally, Quantbot Technologies LP increased its stake in shares of PROCEPT BioRobotics by 151.9% in the first quarter. Quantbot Technologies LP now owns 30,574 shares of the company's stock worth $1,511,000 after acquiring an additional 18,437 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on PRCT. Bank of America upped their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a "buy" rating in a report on Thursday, August 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Truist Financial restated a "buy" rating and issued a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday. Wells Fargo & Company lifted their target price on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Finally, TD Cowen increased their price target on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of "Buy" and an average target price of $88.40.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock traded up $2.30 on Friday, reaching $92.30. The company's stock had a trading volume of 1,016,486 shares, compared to its average volume of 649,826. The company has a quick ratio of 6.49, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $4.82 billion, a P/E ratio of -47.96 and a beta of 1.03. The stock has a 50-day moving average price of $77.39 and a 200-day moving average price of $68.06. PROCEPT BioRobotics Co. has a 52-week low of $27.65 and a 52-week high of $99.34.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. The company had revenue of $58.40 million during the quarter, compared to analyst estimates of $53.30 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm's revenue was up 66.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.51) EPS. Analysts expect that PROCEPT BioRobotics Co. will post -1.74 EPS for the current year.

Insider Buying and Selling

In related news, CEO Reza Zadno sold 288,461 shares of PROCEPT BioRobotics stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total value of $26,249,951.00. Following the sale, the chief executive officer now directly owns 258,445 shares in the company, valued at approximately $23,518,495. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other PROCEPT BioRobotics news, CEO Reza Zadno sold 288,461 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total value of $26,249,951.00. Following the transaction, the chief executive officer now owns 258,445 shares in the company, valued at approximately $23,518,495. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Antal Rohit Desai sold 13,305 shares of PROCEPT BioRobotics stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the sale, the director now directly owns 317,518 shares in the company, valued at approximately $24,248,849.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 468,353 shares of company stock worth $40,196,366 in the last 90 days. Insiders own 17.40% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).